The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CaboRISE: A phase II study evaluating reduced starting dose and dose escalation of cabozantinib as second-line therapy for advanced HCC in patients with compensated liver cirrhosis.
 
Jorg Trojan
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly/ImClone; Merck Serono; Merck Sharp & Dohme; Roche Pharma AG; SERVIER
Speakers' Bureau - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly/ImClone; Merck Serono; Merck Sharp & Dohme; Roche Pharma AG; SERVIER
Research Funding - Bristol-Myers Squibb; Ipsen; PCI Biotech; Roche Pharma AG
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Roche Pharma AG
 
Stefan Pluntke
Consulting or Advisory Role - Bayer
 
Florian van Boemmel
No Relationships to Disclose
 
Ursula Ehmer
Honoraria - Ipsen; Novartis; Roche
Consulting or Advisory Role - Bayer; Eisai
 
Thorsten Oliver Goetze
Consulting or Advisory Role - Bayer; Lilly; MSD Oncology; Roche; SERVIER
Speakers' Bureau - Lilly
Research Funding - Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe (Inst); Gemeinsamer Bundesausschuss
 
Lutz Jacobasch
No Relationships to Disclose
 
Daniel Pink
Speakers' Bureau - Blueprint Medicines (Inst); PharmaMar (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Lilly (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst)
 
Christina Kopp
No Relationships to Disclose
 
Sarah Lehnerts
No Relationships to Disclose
 
Johanna Riedel
No Relationships to Disclose
 
Oliver Waidmann
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Ipsen; Merck; Novartis; Roche; Shire
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Incyte; Ipsen; Merck Serono; MSD; Novartis (I); Roche; SERVIER; Shire
Research Funding - Basilea; Else Kröner-Fresenius-Stiftung; Incyte; Medac; Merck Serono; MSD
Travel, Accommodations, Expenses - Abbvie; Bayer; Bristol-Myers Squibb; Gilead Sciences; Ipsen; Medac; Merck
 
Fabian Finkelmeier
Travel, Accommodations, Expenses - Eisai; Ipsen; MSD
 
Michael Geißler
No Relationships to Disclose